Boutique CRO advantage Sannova Analytical is a small to mid-sized contract research organization with 11-50 employees and a 15+ year track record offering specialized bioanalytical and analytical CMC services. This positions them as a nimble partner for fast, personalized work on complex, novel, and generic therapeutics, presenting an opportunity to pursue high-touch collaboration with biotech startups and mid-stage pharma seeking tailored analytics and rapid turnaround.

End-to-end capabilities The firm emphasizes end-to-end services from characterization to commercialization, backed by a 21,000 square foot lab and cutting-edge instrumentation. This broad scope can be marketed to companies looking to consolidate CRO interactions, reduce vendor risk, and accelerate programs through integrated analytics, method development, and release testing.

Recent leadership shifts Notable leadership changes include appointment of an Executive Chairman in 2022 and a CEO departure in 2025. These dynamics may signal strategic shifts or expansion plans, offering doors for discussions around governance, project scalability, and potential new service lines or geographic or market expansion.

Financial and growth signals Reported revenue range of 10 to 25 million USD, combined with private equity investment activity in 2022. This suggests a growth trajectory and potential for capacity expansion, enabling conversations around large or ongoing programs, long-term contracts, and added resources for complex CMC projects.

Market positioning As a boutique CRO focused on bioanalytical and CMC testing for pharmaceutical and biotech clients, Sannova sits between large CROs and niche specialists. This positions them as a compelling partner for programs requiring specialized expertise with personalized service, which can be leveraged to win mid-to-late-stage projects and capture share from larger CROs on specialized analytical work.